[go: up one dir, main page]

NO20092476L - Antibakterielle polycykliske ureaforbindelser - Google Patents

Antibakterielle polycykliske ureaforbindelser

Info

Publication number
NO20092476L
NO20092476L NO20092476A NO20092476A NO20092476L NO 20092476 L NO20092476 L NO 20092476L NO 20092476 A NO20092476 A NO 20092476A NO 20092476 A NO20092476 A NO 20092476A NO 20092476 L NO20092476 L NO 20092476L
Authority
NO
Norway
Prior art keywords
antibacterial
urea compounds
polycyclic
polycyclic urea
compounds
Prior art date
Application number
NO20092476A
Other languages
English (en)
Inventor
Brian Sherer
Gregory Steven Basarab
Shanta Bist
John Irvin Manchester
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39110548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092476(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20092476L publication Critical patent/NO20092476L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Forbindelser med formel (I) og deres farmasøytisk akseptable salter blir beskrevet. Prosesser for deres tillaging, farmasøytiske sammensetninger som inneholder dem, deres anvendelse som medikamenter og deres anvendelse i behandlingen av bakterielle infeksjoner blir også beskrevet.
NO20092476A 2006-12-04 2009-06-30 Antibakterielle polycykliske ureaforbindelser NO20092476L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86850106P 2006-12-04 2006-12-04
PCT/GB2007/004624 WO2008068470A1 (en) 2006-12-04 2007-12-03 Antibacterial polycyclic urea compounds

Publications (1)

Publication Number Publication Date
NO20092476L true NO20092476L (no) 2009-09-02

Family

ID=39110548

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092476A NO20092476L (no) 2006-12-04 2009-06-30 Antibakterielle polycykliske ureaforbindelser

Country Status (26)

Country Link
US (1) US7674801B2 (no)
EP (1) EP2102199B1 (no)
JP (1) JP2010511682A (no)
KR (1) KR20090086629A (no)
CN (1) CN101627038A (no)
AR (1) AR064130A1 (no)
AT (1) ATE507225T1 (no)
AU (1) AU2007330600B2 (no)
BR (1) BRPI0720057A2 (no)
CA (1) CA2670870A1 (no)
CL (1) CL2007003470A1 (no)
CO (1) CO6190609A2 (no)
DE (1) DE602007014256D1 (no)
EC (1) ECSP099451A (no)
ES (1) ES2363178T3 (no)
IL (1) IL198865A0 (no)
MX (1) MX2009005603A (no)
NO (1) NO20092476L (no)
NZ (1) NZ578159A (no)
PE (1) PE20081583A1 (no)
RU (1) RU2469034C2 (no)
SA (1) SA07280667B1 (no)
TW (1) TW200831503A (no)
UA (1) UA96964C2 (no)
UY (1) UY30759A1 (no)
WO (1) WO2008068470A1 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
TW200940537A (en) * 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
UY31865A (es) * 2008-06-04 2010-01-29 Astrazeneca Ab Derivados de urea heterocíclicos y métodos para la utilización de los mismos
EA201001858A1 (ru) * 2008-06-04 2011-08-30 Астразенека Аб Гетероциклические производные мочевины для лечения бактериальных инфекций
AR073760A1 (es) * 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201102065A (en) * 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2010142978A1 (en) * 2009-06-08 2010-12-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2011024004A1 (en) 2009-08-26 2011-03-03 Astrazeneca Ab Heterocyclic urea derivatives useful for treatment of bacterial infection
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CN102844305B (zh) 2010-03-31 2014-07-02 埃科特莱茵药品有限公司 抗菌异喹啉-3-基脲衍生物
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
SG187795A1 (en) 2010-08-11 2013-03-28 Millennium Pharm Inc Heteroaryls and uses thereof
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013542941A (ja) 2010-10-13 2013-11-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
SG191946A1 (en) 2011-01-14 2013-08-30 Vertex Pharma Pyrimidine gyrase and topoisomerase iv inhibitors
WO2012097270A1 (en) 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
TWI535714B (zh) 2011-01-14 2016-06-01 維泰克斯製藥公司 旋轉酶抑制劑（ｒ）－１－乙基－３－［６－氟－５－［２－（１－羥基－１－甲基－乙基）嘧啶－５－基］－７－（四氫呋喃－２－基）－１ｈ－苯并咪唑－２－基］脲之固體形式
CA2824519C (en) 2011-01-14 2020-06-16 Vertex Pharmaceuticals Incorporated Process of making gyrase and topoisomerase inhibitors
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
EP2721026B1 (en) 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
CN104125947A (zh) * 2011-12-21 2014-10-29 生物区欧洲有限公司 杂环脲化合物
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
SG11201405895UA (en) 2012-03-27 2014-10-30 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
CN104411314B (zh) 2012-07-09 2017-10-20 詹森药业有限公司 磷酸二酯酶10的抑制剂
AR093226A1 (es) 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
HK1218864A1 (zh) * 2013-03-15 2017-03-17 森普拉制药公司 用於制备大环内酯抗菌剂的收敛方法
MX2016009135A (es) 2014-01-14 2016-10-05 Millennium Pharm Inc Heteroarilos y usos de estos.
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
CN105067814A (zh) * 2015-07-24 2015-11-18 中国科学院成都生物研究所 解旋酶水解atp活性测定方法
WO2018174288A1 (ja) 2017-03-24 2018-09-27 大正製薬株式会社 ２（１ｈ）－キノリノン誘導体
JP7344125B2 (ja) * 2017-03-30 2023-09-13 エフ． ホフマン－ラ ロシュ アーゲー 細菌感染の治療及び予防のための新規ピリド［２，３－ｂ］インドール化合物
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
CN111116559A (zh) * 2018-11-01 2020-05-08 复旦大学 吡啶脲类化合物及其制备方法和制药用途
CN115703738B (zh) * 2021-08-16 2024-06-21 中国科学院上海药物研究所 含2-芳杂环取代的脲类化合物、其制备方法和用途
KR20250005373A (ko) 2022-04-22 2025-01-09 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0589985A1 (en) * 1991-06-21 1994-04-06 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
US6410533B1 (en) * 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
EP1341769B1 (en) * 2000-12-15 2007-10-17 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
JPWO2003089431A1 (ja) * 2002-04-19 2005-08-25 住友製薬株式会社 新規なカルバペネム化合物
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
MX2007004179A (es) 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
AU2005321946B2 (en) * 2004-12-23 2012-08-16 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US20080269214A1 (en) * 2005-03-04 2008-10-30 Astrazeneca Ab Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
UA96735C2 (en) * 2005-05-24 2011-12-12 Мерк Сероно Са Thiazole derivatives and use thereof
FR2889190A1 (fr) * 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
CA2648785A1 (en) 2006-03-23 2007-09-27 Prolysis Ltd. Antibacterial agents
WO2007116106A1 (es) * 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents

Also Published As

Publication number Publication date
CO6190609A2 (es) 2010-08-19
HK1136277A1 (en) 2010-06-25
IL198865A0 (en) 2010-02-17
RU2009125441A (ru) 2011-01-27
ES2363178T3 (es) 2011-07-26
ATE507225T1 (de) 2011-05-15
AU2007330600B2 (en) 2012-05-10
MX2009005603A (es) 2009-06-08
CN101627038A (zh) 2010-01-13
BRPI0720057A2 (pt) 2013-12-17
CA2670870A1 (en) 2008-06-12
ECSP099451A (es) 2009-07-31
DE602007014256D1 (de) 2011-06-09
KR20090086629A (ko) 2009-08-13
UA96964C2 (ru) 2011-12-26
RU2469034C2 (ru) 2012-12-10
WO2008068470A1 (en) 2008-06-12
JP2010511682A (ja) 2010-04-15
CL2007003470A1 (es) 2008-08-22
EP2102199A1 (en) 2009-09-23
US20080132546A1 (en) 2008-06-05
UY30759A1 (es) 2008-07-31
EP2102199B1 (en) 2011-04-27
NZ578159A (en) 2012-01-12
SA07280667B1 (ar) 2010-12-07
PE20081583A1 (es) 2008-12-20
AU2007330600A1 (en) 2008-06-12
US7674801B2 (en) 2010-03-09
TW200831503A (en) 2008-08-01
AR064130A1 (es) 2009-03-11

Similar Documents

Publication Publication Date Title
NO20092476L (no) Antibakterielle polycykliske ureaforbindelser
NO20074703L (no) Antibakterielle piperidinderivater
NO20083250L (no) Antibakterielle pyrrolopyridiner, pyrrolopyrimidiner og pyrroloazepiner
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
WO2008020229A3 (en) Antibacterial pyrrolecarboxamides
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
WO2008154642A3 (en) Antibacterial agents
WO2010038081A3 (en) 4-amino-5- (hetero) aryl-2-phenylamino-pyrimidine or pyridine and their use as dna gyrase and/or topoisomerase iv inhibitors
WO2010084115A3 (en) Antiviral agents
NO20090628L (no) Pyridizinon derivativater
MY150958A (en) Compounds for the treatment of multi-drug resistant bacterial infections
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
MX2009013501A (es) Compuestos piperidinicos y sus usos.
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
WO2006092599A3 (en) Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
NO20092655L (no) 2-kinolinon- og 2-kinoksalinonderivater og deres anvendelse som antibakterielle midler
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MY148124A (en) Preparation of a crystalline antibiotic substance
WO2006087544A8 (en) Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer
NO20083441L (no) Benzoisoindolderivater for behandling av smerte

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application